Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
7/31/2025
China's Plan to Boost Drug Coverage by Commercial Insurers No 'Magic W...
7/29/2025
Merck Faces China Headwinds as Gardasil Pause Drags on Q2 Results
7/29/2025
Pfizer Launches Landmark Pneumococcal Vaccine Trial in China, Pioneeri...
7/26/2025
China's Sciwind in Licensing Talks to Bring Weight-Loss Drug to U.S. M...
7/25/2025
Newish Secures Series B1 Investment to Propel Nucleic Acid Cancer Vac...
7/23/2025
China-Singapore Nanovaccine Prevents Cancer Recurrence in Animals
7/22/2025
Chimigen Raises ~CNY 170M to Advance Cancer and HepB Vaccines
7/18/2025
SKBio Wins Chinese Clinical Trial Approval for GBP410
7/12/2025
China's First 9-Valent HPV Vaccine Launches at 60% Discount, Undercutt...
7/11/2025
Regenelead's KRAS-Targeted Cancer Vaccine Approved for Clinical Trials...
7/4/2025
AstraZeneca Eyes $15B Deal for Summit's Chinese-Developed Lung Cancer ...
7/3/2025
Vaccine Sales Collapse in China as MNCs Struggle with Local Competitio...
7/2/2025
Simcere's Suvemcitug Approved in China for Platinum-Resistant Ovarian ...
7/2/2025
NMPA Grants Marketing Approval to GeneScience's Firsekibart for Acute ...
7/2/2025
Betta's Tibremciclib Approved in China for Advanced HR+/HER2– Breast ...
7/1/2025
Biological E and China's Recbio Partner to Bring HPV9 Vaccine to India...
7/1/2025
Hengrui's Ivarmacitinib Approved in China for Severe Alopecia Areata
7/1/2025
Revolution Medicines and Summit Therapeutics Launch RAS-Targeting Comb...
6/30/2025
CDE Reopens Public Consultation on Revised Technical Guidelines for Co...
6/27/2025
Theravance Partner Viatris Lands NMPA Approval for YUPELRI, Unlocking ...
6/26/2025
Vor Bio Secures ex-China Global Rights to RemeGen's Telitacicept
6/23/2025
Sciwind's Ecnoglutide Achieves 15.4% Weight Loss in Chinese Obesity Ph...
6/20/2025
CanSinoBIO Obtained NDA Approval for its 13-Valent Pneumococcal Polysa...
6/17/2025
NMPA Holds Meeting to Review QMS in Vaccine Regulation, Pharma Manufa...
6/12/2025
Dizal to Showcase Breakthrough Data on Hematologic Oncology Assets at ...
6/12/2025
Viatris Wins NMPA Approval for Once‑Daily Nebulized COPD Therapy Yupe...
6/10/2025
Gavi Launches $224M Arbitration Claim Against Clover Biopharma Over CO...
6/9/2025
Sihuan's Chinese NDA for Breast Cancer Drug Bireociclib Accepted
6/6/2025
AbbVie's Rinvoq (Upadacitinib) Gains Approval in China for Giant Cell ...
6/4/2025
China Approves First Homegrown 9-Valent HPV Vaccine
Page:
1
/
73
Total number of articles:
2177
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit